Zentek’s Breakthrough Aptamer Platform Shows Promise in Fighting COVID-19

written by InvestorNews | July 25, 2023

In a recent interview conducted by Tracy Weslosky of InvestorIntel, Greg Fenton, the CEO & Director of Zentek Ltd. (NASDAQ: ZTEK | TSXV: ZEN), unveiled some thrilling developments surrounding the company’s revolutionary aptamer platform. With an exclusive global license from McMaster University, this groundbreaking platform has demonstrated remarkable success in pre-clinical animal model tests as a potential prophylactic or therapeutic for SARS-CoV-2, the virus responsible for the ongoing COVID-19 pandemic. Spearheaded by Dr. Yingfu Li’s team at McMaster, this platform harnesses a series of synthetic molecules known as aptamers, exhibiting a high affinity for the SARS-CoV-2 spike protein.